KEMPHARM INC
KEMPHARM INC logo
KMPH

KEMPHARM INC (KMPH)

$4.821.26%

Market is closed
– opens on 8 PM, 02 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$4.72
Day's Range
$4.9
$4.0
52-Week Range
$9.43
1 month return15.3%
3 month return15.15%
1 year return42.09%
5 year return91.69%

Company Information

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
OrganizationKEMPHARM INC
Employees24
CEOMr. Richard W. Pascoe
IndustryHealth Technology

Analyst Recommendation

based on 9 analysts ratings

Buy
88%
Buy
11%
Hold
0%
Sell

Based on 9 Wall street analysts offering stock ratings for KEMPHARM INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 304.56%

Current

$4.82

Target

$19.5

Recommendation Trend

Based on 9 analyst

Current1M Ago3M Ago
Buy
8
7
7
Hold
1
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization
161.3M
Book Value
$2.72
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.3
PE Ratio
15.58
PEG Ratio
0.0
Wall Street Target Price
19.5

Valuation

Trailing PE15.58
Forward PE263.16
Price/Book (mrq)
1.72
Enterprise Value
99.5M
Enterprise Value/Revenue
9.28
Enterprise Value/Ebitda
-2.85

Technicals

Beta
2.37
50 Day MA
5.48
200 Day MA
5.23

Institutional Holdings

Vanguard Group Inc

4.0%

HealthInvest Partners AB

2.17%

LAURION CAPITAL MANAGEMENT LP

1.69%

Janney Montgomery Scott LLC

1.39%

Millennium Management LLC

0.98%

Geode Capital Management, LLC

0.92%

Discover more

Frequently Asked Questions

What is KEMPHARM INC share price today?

Can Indians buy KEMPHARM INC shares?

How can I buy KEMPHARM INC shares from India?

Can Fractional shares of KEMPHARM INC be purchased?

What are the documents required to start investing in KEMPHARM INC stocks?

What are today’s High and Low prices of KEMPHARM INC?

What are today’s traded volumes of KEMPHARM INC?

What is today’s market capitalisation of KEMPHARM INC?

What is the 52 Week High and Low Range of KEMPHARM INC?

How much percentage KEMPHARM INC is down from its 52 Week High?

How much percentage KEMPHARM INC is up from its 52 Week low?

What are the historical returns of KEMPHARM INC?

Who is the Chief Executive Officer (CEO) of KEMPHARM INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*